Deal Spree Continues as Celgene Nabs Juno in $9B Deal Post author:Sam Post published:January 21, 2018 Post category:BioPharma The announcement sent shares of Juno soaring more than 27 percent in pre-market trading to $86.26. Source: BioSpace You Might Also Like How Sweet It Is: Dynavax Finally Wins FDA OK for Hep B Vaccine Heplisav November 9, 2017 Who Might or Might Not Buy Regeneron, And Why January 19, 2017 Roche Launches The Cobas EGFR Mutation Test V2 For Use With Either Plasma Or Tumor Tissue Samples March 13, 2017
Roche Launches The Cobas EGFR Mutation Test V2 For Use With Either Plasma Or Tumor Tissue Samples March 13, 2017